Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

unknown117%
terminated233%
completed350%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma

NCT02851784
terminatedphase_1

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

NCT02757391
terminatedphase_1

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

NCT01239368
completedphase_1

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

NCT01894373
unknownphase_2

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

NCT00986557
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02851784Phase 2

Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma

Completed
NCT02757391Phase 1

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Terminated
NCT01239368Phase 1

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Terminated
NCT01894373Phase 1

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

Completed
NCT00986557Phase 2

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Unknown
NCT00324623Phase 1

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6